BridgeMD
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation
EU CTIS ID: 2022-501419-15-00
What this study is testing
To evaluate if milvexian is non-inferior to apixaban for the composite of stroke and non-CNS systemic embolism.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Minimum age of 18 years
- Medically stable and appropriate for chronic antithrombotic treatment
- Atrial fibrillation eligible to receive anticoagulation therapy.
- Participant must satisfy one or both of the following categories of risk factors (a or b): a. One or more of the following risk factors: i. Age ≥75 years ii. History of any type of stroke, including symptomatic stroke of any kind and silent brain infarcts or cerebral microbleeds b. Two or more of the following risk factors: i. Age between 65 and 74 years ii. Hypertension iii. Diabetes mellitus iv. Atherosclerotic vascular disease v. Heart Failure
You likely can't join if
- Hemodynamically significant valve disease or those with valve disease that will potentially require surgical valve replacement during the study
- Any condition other than AF that requires chronic anticoagulation
The study team makes the final eligibility decision.
Where it's taking place
- Canada
- Israel
- China
- Korea, Republic of
- Chile
- Philippines
- New Zealand
- Singapore
- Malaysia
- Australia
- Turkey
- India
- United States
- Argentina
- Taiwan
- Brazil
- Japan
- Serbia
- South Africa
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Canada; Israel; China; Korea, Republic of; Chile; Philippines and 14 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.